Pacemaker syndrome in single-chamber ventricular pacing

Single-chamber ventricular pacing offers reliable protection against dangerous bradycardia when atrial sensing or pacing is unsuitable. Yet a device that protects the heart rate can leave a person with disabling symptoms. Loss of coordinated atrial and ventricular contraction, together with abnormal ventricular activation, may generate pacemaker syndrome that is overlooked because the pacemaker appears to function normally.

Symptoms commonly include fatigue, breathlessness on exertion, lightheadedness, presyncope, palpitations and chest discomfort. Some patients notice neck pulsations or a forceful heartbeat. The presentation can be subtle, particularly in older adults, and may be attributed to heart failure, medication effects, anxiety or reduced fitness rather than pacing-related physiology.

Recognition begins with a timeline: symptoms before and after implantation, changes after programming, and the proportion of time spent pacing. Device interrogation, a 12-lead ECG and echocardiography help separate several mechanisms.

An upgrade is not automatically the answer. Some symptoms reflect reversible disease, unsuitable rate settings or an underlying cardiomyopathy. When pacing-related dysfunction is likely, restoring atrial synchrony or improving ventricular activation may help. The best option depends on rhythm, ventricular function, comorbidity, technical feasibility and the patient’s goals.

Physiological causes of pacing-related symptoms

In rate-responsive ventricular-only pacing, such as VVIR, output is delivered when no intrinsic ventricular event is sensed. Preserved sinus rhythm continues to activate the atrium independently. Atrial contraction then occurs at the wrong time, sometimes against closed mitral and tricuspid valves, reducing filling and increasing regurgitation. This atrioventricular dyssynchrony explains many pacemaker syndrome symptoms.

Ventricular timing adds another mechanism. Right ventricular apical pacing can activate the septum and inferolateral wall in an abnormal sequence, impairing systolic efficiency. Patients with normal ventricular function may tolerate substantial pacing, whereas reduced ejection fraction, scar or longstanding hypertension can amplify the loss of synchrony.

Not every symptom follows from atrial or ventricular dyssynchrony. Inappropriate sensor-driven pacing, an underlying atrial arrhythmia, ischaemia or progression of heart failure may dominate. A device can therefore be technically normal while the pacing strategy remains physiologically poor. Separating these causes prevents an unnecessary or unsuitable lead upgrade.

Recognising the clinical pattern

A useful history asks whether dizziness follows a missed beat, whether breathlessness appears at a particular pacing rate, and whether symptoms began after implantation, lead revision or a medication change. Palpitations may indicate an atrial arrhythmia rather than pacing itself. Asking about posture, exertion and recent falls can reveal presyncope that was previously dismissed.

Examination may show variable blood pressure, hypotension, mitral regurgitation, raised jugular venous pressure or cannon atrial waves. None is specific. Anaemia, thyroid disease, ischaemia, depression and deconditioning can produce similar fatigue. New neurological symptoms, exertional syncope or rapidly worsening heart failure need prompt assessment rather than routine upgrade referral.

Clinicians can consult the journal’s arrhythmia education resources for peer-reviewed device and electrophysiology material. Device clinics can provide a symptom diary, an interrogation printout and a plain-language explanation of the relevant findings.

Device interrogation and targeted investigations

Interrogation should establish the current mode, pacing burden, lower and upper rate limits, sensor behaviour, capture thresholds, lead impedance and battery status. It should compare intrinsic and paced rhythm parameters and review stored electrograms around symptomatic events. A high ventricular pacing percentage makes pacing-related symptoms more plausible, but timing and underlying disease still matter.

A 12-lead ECG during pacing can show atrial activity, pacing intervals and ventricular activation morphology. Ambulatory monitoring may correlate symptoms with pacing, pauses or tachyarrhythmia. Programming can reduce unnecessary pacing or correct an inappropriate rate response, but no VVI setting can create atrial synchrony.

Echocardiography assesses ejection fraction, chamber size, regional wall motion, right ventricular function and valvular regurgitation. Cardiac amyloidosis deserves particular attention: conduction disease, ventricular wall thickening, a low-voltage ECG and unexplained pacing intolerance may overlap. The journal’s discussion of recognition and palliation provides a useful framework for multidisciplinary care.

Separating pacing syndrome from other causes

Symptoms that occur only during ventricular pacing support a pacing-related mechanism. A useful comparison is how the patient feels with intrinsic ventricular conduction, when safe, against a period with pacing at the programmed rate. Device counters and ambulatory recordings can establish whether a particular pacing burden coincides with fatigue, dizziness or dyspnoea.

Atrial tachyarrhythmias can interfere with single-chamber pacing and require separate treatment. Reviewing medication timing, beta-blockers, rate-response settings and whether pauses follow sensor-driven rate changes can reveal an avoidable problem. Occasionally, programming optimisation or a lower base rate with appropriate safety backup is sufficient, provided bradycardia protection remains adequate.

Persistent symptoms with substantial pacing, evidence of AV dyssynchrony or declining ventricular function justify specialist review. This does not mean every symptomatic patient needs more hardware. Heart failure therapy, rhythm control, rehabilitation and treatment of anaemia or thyroid disease may improve symptoms that appear to originate from the device.

Selecting an upgrade strategy

For a pacemaker-dependent patient in sinus rhythm, adding an atrial lead and converting to DDD or DDD(R) can restore coordinated atrial timing. With complete heart block, a suitably short programmed AV delay preserves the atrial contribution to ventricular filling. Suitability depends on atrial rhythm, AV conduction, age, lead access and the likelihood of meaningful symptom benefit.

Preserved ventricular function and isolated loss of atrial synchrony may respond better to dual-chamber pacing than to resynchronisation therapy. With impaired ejection fraction, ventricular dyssynchrony or a high expected pacing burden, biventricular pacing or conduction-system pacing may be considered. His bundle and left bundle branch area pacing seek physiologic activation, while CRT provides biventricular support. Guideline indications and comparative evidence continue to evolve.

Atrial fibrillation changes the decision. A dual-chamber system generally offers no benefit when there is no persistent sinus rhythm, so treatment centres on reliable ventricular support, ventricular synchrony and whether rhythm control would alter the strategy. In advanced frailty or amyloidosis, improving comfort may take priority over restoring every physiological parameter.

Procedural risks deserve equal weight. Lead insertion can injure veins, and adding hardware increases infection risk. An existing lead may be retained when appropriate, while replacement or extraction may be required for infection, failure or poor thresholds. Decisions should include expected improvement, recovery, lead longevity, future revisions and the consequences of doing nothing.

Australian access and follow-up realities

Australian reimbursement is mixed. Medicare rebates may cover eligible implantation and upgrade components; public hospitals provide device pathways, while private care can leave substantial gaps for generators, leads, specialist fees and hospital costs. Request an itemised estimate covering the procedure, stay, device, follow-up and any monitoring subscription.

Complex upgrades and lead extraction are concentrated in tertiary electrophysiology services in Melbourne, Sydney and Brisbane. Routine device clinics are also available in other capitals and regional centres, but a patient in Perth, Adelaide or Hobart may need to travel for a particular technique or operator. Referral pathways and waiting lists differ between public and private systems.

For people in rural and remote areas, including communities around Alice Springs and in northern Queensland, telehealth can support interrogation and medication review between visits. It cannot replace an examination when infection, pocket swelling or lead injury is suspected. Plans should identify where urgent review and travel would occur, and include local health services and family support where appropriate.

Remote monitoring is a substantial part of the Australian device market. Vendor apps, clinic platforms and consumer subscriptions differ in cost and coverage; eligible remote consultations may attract Medicare rebates, but transmission services and clinical reviews may be charged separately. Clarify who monitors transmissions, response times, after-hours cover and how data are protected under Australian privacy expectations.

Multidisciplinary management and monitoring

Device follow-up is multidisciplinary. The treating cardiologist, electrophysiologist, device nurse, pharmacist, general practitioner and imaging team should agree who reviews symptoms, medications, wound healing, pacing burden and battery status. Early review after an upgrade checks lead position and capture, while stable patients can move to a planned remote or face-to-face schedule.

Record a baseline after intervention so benefit can be judged against fatigue, walking tolerance, blood pressure, presyncope and ventricular pacing. Heart failure treatment and supervised rehabilitation remain important when the underlying diagnosis persists. A device change should not obscure the need to optimise other cardiovascular medicines or address frailty.

A clear escalation pathway matters. Fever with redness or discharge around a pocket, new unexplained syncope, worsening dyspnoea or repeated device alerts needs timely clinical review, with urgent assessment for infection or lead complication. For advanced disease, palliative care can run alongside device management, focusing on comfort, communication and reducing avoidable device-related burden.

If you have persistent fatigue, dizziness or breathlessness after ventricular-only pacing, arrange a review with your cardiologist, general practitioner or device clinic. Bring your device card, interrogation report, medication list and a symptom diary linking symptoms to activity and timing. Ask about pacing burden, atrial synchrony, ventricular activation and whether the current mode still matches your rhythm and needs.

Request a coordinated plan covering investigation, programming review, upgrade options, expected benefit, procedural risks, travel and monitoring. Act promptly for signs of infection or recurrent syncope. A structured assessment can turn vague symptoms into a clear pathway and prevent months of avoidable discomfort.